

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**May 17, 2022**

---

**I Continuing Review**

**10398**, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma (Protocol Version Date 08/17/21)

---

**II Amendment**

**10144**, A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects (Protocol Version Date 03/16/22)

---

**III Amendment**

**10404**, A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma (Protocol Version Date 04/12/22)

---

**IV Memos**

**10096**, A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) (Protocol Version Date 12/10/21)

---